Chimerix Inc (CMRX) Short Interest Update

Share on StockTwits

Chimerix Inc (NASDAQ:CMRX) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 710,480 shares, an increase of 37.2% from the February 15th total of 517,756 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average daily trading volume, of 543,767 shares, the days-to-cover ratio is currently 1.3 days.

Several equities research analysts have weighed in on CMRX shares. ValuEngine upgraded Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Zacks Investment Research cut Chimerix from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. HC Wainwright reiterated a “buy” rating on shares of Chimerix in a report on Wednesday, February 6th. Finally, Citigroup dropped their price objective on Chimerix from $4.25 to $2.00 and set a “neutral” rating for the company in a report on Wednesday, March 6th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Chimerix currently has a consensus rating of “Hold” and an average target price of $5.06.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Chimerix by 6.2% in the 3rd quarter. BlackRock Inc. now owns 3,711,445 shares of the biopharmaceutical company’s stock worth $14,439,000 after acquiring an additional 215,268 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Chimerix by 2.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,612,871 shares of the biopharmaceutical company’s stock worth $6,715,000 after acquiring an additional 56,347 shares in the last quarter. Vanguard Group Inc raised its position in shares of Chimerix by 6.4% in the 3rd quarter. Vanguard Group Inc now owns 2,115,044 shares of the biopharmaceutical company’s stock worth $8,228,000 after acquiring an additional 126,847 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Chimerix by 6.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,115,044 shares of the biopharmaceutical company’s stock worth $8,228,000 after acquiring an additional 126,847 shares in the last quarter. Finally, Morgan Stanley raised its position in shares of Chimerix by 28.8% in the 3rd quarter. Morgan Stanley now owns 2,041,150 shares of the biopharmaceutical company’s stock worth $7,940,000 after acquiring an additional 456,290 shares in the last quarter. 73.65% of the stock is owned by hedge funds and other institutional investors.

NASDAQ CMRX opened at $2.05 on Friday. Chimerix has a fifty-two week low of $1.74 and a fifty-two week high of $5.76. The company has a market capitalization of $100.79 million, a price-to-earnings ratio of -1.43 and a beta of 1.34.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.07. Chimerix had a negative return on equity of 35.97% and a negative net margin of 951.77%. As a group, sell-side analysts forecast that Chimerix will post -1.46 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Chimerix Inc (CMRX) Short Interest Update” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/4224897/chimerix-inc-cmrx-short-interest-update.html.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Further Reading: SEC Filing

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Buying: ANNALY CAP MGMT/SH  Director Acquires 30,000 Shares of Stock
Insider Buying: ANNALY CAP MGMT/SH Director Acquires 30,000 Shares of Stock
Hastings Group  Receives New Coverage from Analysts at Panmure Gordon
Hastings Group Receives New Coverage from Analysts at Panmure Gordon
Asbury Automotive Group  Upgraded to “Buy” by Zacks Investment Research
Asbury Automotive Group Upgraded to “Buy” by Zacks Investment Research
$1.27 Earnings Per Share Expected for Tenneco Inc  This Quarter
$1.27 Earnings Per Share Expected for Tenneco Inc This Quarter
ALLETE Inc  Shares Bought by Dimensional Fund Advisors LP
ALLETE Inc Shares Bought by Dimensional Fund Advisors LP
Financial Gravity Companies Inc. Takes $163,000 Position in Facebook, Inc.
Financial Gravity Companies Inc. Takes $163,000 Position in Facebook, Inc.


© 2006-2019 Ticker Report